Energy & Vitality

Persistent low energy is usually a symptom, not a diagnosis. Sleep, thyroid, B-vitamin deficiency, anemia, depression, and sleep apnea are the common upstream causes — peptides are not the diagnostic. If you haven't worked through those with your doctor yet, start there.

This protocol assumes you've ruled out the obvious causes and your labs are clean. If you still feel persistently low-energy after that workup, this is the peptide-specific path most people work through. Each phase builds on the last with decision criteria so you know when to advance, when to pivot, and when to stop.

It's not the only path. Your starting point depends on what you've already tried, your specific bottleneck, and your clinician's input.

Phases

1. Phase 1 — Establish baseline

   weeks 1-4

   Cofactor restoration is the cheapest, lowest-risk intervention with the clearest signal. If B-vitamin deficiency was the bottleneck, you'll feel it within 2-3 weeks. If it wasn't, you've ruled out a confounder before adding anything fancier.

   • B12 (Methylcobalamin)1 mg · weekly · morning

     Bioactive B12 form that bypasses methylation bottlenecks. Weekly SubQ at 1mg is the standard deficiency-correction dose.

   What “working” looks like

   Noticeable afternoon-energy improvement within 2-3 weeks. Less reliance on caffeine. Sustained morning energy after waking.

   Decision criteria

   If working by week 4: maintain through Phase 2. If not working by week 4: deficiency wasn't the bottleneck — move to Phase 2.

   Labs to pull

   • Serum B12
   • Methylmalonic acid (MMA) — more sensitive than serum B12 alone
   • Homocysteine
   • Ferritin
   • TSH + free T3 — rule out thyroid
   • Complete metabolic panel + lipid panel

2. Phase 2 — Mitochondrial layer

   weeks 4-12

   Add SS-31. Mitochondrial-targeted antioxidant that stabilizes inner-membrane cardiolipin. This is the most common bottleneck for "tired all the time" presentations after deficiency is ruled out. Strongest evidence is in cardiomyopathy populations; off-label use in healthy adults is Tier 3.

   • SS-31 (Elamipretide)5 mg · daily · morning

     Mitochondrial-targeted antioxidant. 5mg SubQ daily is the studied range; do not escalate dose if not working.

   • B12 (Methylcobalamin)1 mg · weekly · morning

     Maintain Phase 1 cofactor support throughout — energy improvements compound when the substrate layer stays stable.

   What “working” looks like

   Morning energy ≥30 minutes sooner after waking. Afternoon dip softens by 4-6 weeks. Exercise tolerance improves — easier to start workouts, faster recovery.

   Decision criteria

   If working by week 8: continue and consider Phase 3. If not working by week 6: do not escalate dose. Reassess sleep, thyroid, mood. Consider workup for chronic inflammation (hs-CRP, ESR).

   Labs to pull

   • Repeat baseline panel from Phase 1 if energy hasn't moved
   • hs-CRP — chronic low-grade inflammation
   • ESR — adjunct inflammation marker

3. Phase 3 — Add or transition

   weeks 12+

   Layer in MOTS-c and NAD+ support. MOTS-c activates AMPK and improves mitochondrial bioenergetics through a different mechanism than SS-31. NAD+ provides the redox substrate both peptides depend on. Combining addresses different points on the same axis. All Tier 3 in healthy adults.

   • SS-31 (Elamipretide)5 mg · daily · morning

     Continue Phase 2 antioxidant support — discontinuing reverses the cardiolipin-stabilization gains.

   • MOTS-c5 mg · MWF · morning

     AMPK activator. 5mg SubQ on Mon/Wed/Fri layers cleanly onto SS-31 without dose escalation on either.

   • Nicotinamide Riboside (NR)300 mg · daily · morning

     Oral NAD+ precursor. 300mg daily is the studied range that reliably raises blood NAD+ in humans. NR is interchangeable with NMN at the substrate level.

   • B12 (Methylcobalamin)1 mg · weekly · morning

     Maintain the cofactor layer — full stack only works with the substrate baseline intact.

   What “working” looks like

   Sustained morning energy, sharper cognition, faster workout recovery, more consistent day-to-day. This is the maintenance state.

   Decision criteria

   If working: continue indefinitely with periodic reassessment (every 6 months — labs + symptom review). If not adding meaningful benefit over Phase 2: drop back to Phase 2 (cheaper, simpler). If new symptoms emerge: pause everything, work with clinician on differential.

Often combined with

• Recovery from Injury

  Cofactor and mitochondrial support in Phase 1 + 2 of Energy overlap cleanly with the tissue-repair phases in Recovery from Injury. People recovering from injury often present with low energy as a secondary symptom — the two protocols stack without conflict.